







































NOS = no special type.
Available online http://breast-cancer-research.com/content/3/1/001
Introduction
Two epithelial cell types, present in roughly equal
numbers, line the entire normal duct and lobular system of
the human breast. There is an inner ‘luminal’ or ‘secretory’
cell layer and an incomplete outer myoepithelial cell layer.
Since the myoepithelium is incomplete, some luminal cells
reach the basement membrane. The myoepithelial cells, in
contrast, do not reach the luminal surface. The myoepithe-
lial cells are attached to the basement membrane by
hemidesmosomes and to the adjacent luminal cells by
desmosomes. The cells have pinocytic vesicles, contain-
ing microfilaments and dense bodies resembling smooth
muscle. The myofilaments are not as well developed in the
cells lining the acini compared with those lining the termi-
nal ducts and the interlobular ducts. The myoepithelial cell
is, in some respects, the Cinderella of the breast. It has
been largely ignored in the context of breast cancer.
Although the cell’s auxiliary role in lactational physiology is
well recognised, this is a minor component of the process
and is limited to assisting milk ejection during suckling in
response of oxytocin. What, however, of the other 99% of
time? Those with a more philosophical bent have found it
hard to believe that the contractile function represents the
be all and end all of myoepithelial cell function.
Its position, interposed between stroma and lumen, places
it in an ideal situation to control many aspects of luminal
function. It could regulate polarity, electrolyte and fluid flow,
filter and process signals of endocrine or paracrine nature,
and perhaps act as an intermediary in such signalling
processes by passing information both inwards and out-
wards in a paracrine fashion or via intra-epithelial gap-junc-
tions [1]. One school of thought has indeed invested the
myoepithelium with great significance as a paracrine
inhibitor of invasion and thus an inhibitor of tumour progres-
sion [2]. Other workers have proposed that, in the absence
of fully differentiated myoepithelial cells, a failure to
sequester local growth factor such as b-fibroblast growth
factor may contribute to uncontrolled growth of malignant
breast cells [3]. That said, there is only limited direct experi-
mental information that addresses these hypotheses
[2,4–6]. Perhaps the most convincing experiment would
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be removal of the myoepithelium either by gene knockout
or by targeted chemotherapeutic ablation, in a manner
similar to that described for the luminal compartment [7].
Many key genes undoubtedly impact on myoepithelial
function but, if deletions are lethal at early stages of
embryonic or postpartum life, then their effects on mature
myoepithelial function cannot be assessed. In this context,
the transgenic fat-pad model [8,9] and the rarely used
xenograft model [10] could be useful experimental tools if
combined with appropriate cell separation techniques.
We and other workers have developed methods to sepa-
rate pure populations of luminal and myoepithelial cells
from the mouse [11], the rat [12,13] and, most impor-
tantly, from humans [14–16]. These methods give us, in
principle, the means to analyse the role of the myoepithe-
lial cell in detail, at least in vitro. In practice, no group has
exploited this with vigour, due in part to an emphasis on
comparing luminal cells with invasive cancer, discarding
the myoepithelial cells as an unwanted contaminant. This
is also due to the fact that the essential contractile aspect
of myoepithelial function, in the form of organised myofila-
ments, is progressively lost under conventional culture
conditions in human, rat and mouse cells [11,12,14]. The
human myoepithelial cells do, however, retain a basal phe-
notype that is stable, retained during cloning, and that
allows them to be readily distinguished from luminal cells.
The use of complex culture environments such as extracel-
lular matrix-containing substrates can delay or reduce this
‘de-differentiation’ to some extent [17]. However, there is
no disguising the fact that, once they have been separated
and introduced into long-term culture, myoepithelial cells
are but a shadow of their former selves. It is perhaps
understandable under these circumstances that no great
effort has been made in analysing their detailed physiol-
ogy. There is an urgent need for more short-term culture
experiments involving separation and controlled recombi-
nation of the major breast cell types in order to reveal their
functions and interactions in the non-lactating mammary
gland. As a step in this direction, a highly detailed analysis
of the patterns of protein expression from freshly sepa-
rated human luminal and myoepithelial cells has been
completed recently using proteomic technology [18].
A major enigma in myoepithelial biology and pathobiology
is the apparent infrequency with which this cell type gives
rise to tumours. The cells are an integral part of benign
lesions such as sclerosing adenosis and papillomata. Their
contribution to breast malignancy has been unclear.
Tumours showing myoepithelial differentiation have been
reported more frequently in the past 20 years and include
adenoid cystic carcinoma, adenosquamous carcinoma,
adenomyoepithelioma, pure myoepithelial carcinoma and
poorly differentiated myoepithelial rich carcinoma [19–21].
These tumours appear to be rare in clinical practice [22]
and reports in the literature are generally of small series or
isolated case reports [20,22–24]. The contribution of
myoepithelial cells to ordinary ductal carcinomas is also
unclear and reports suggest that 2–18% of so-called
ductal carcinomas–no special type (NOS) show focal or
diffuse myoepithelial differentiation by immunohistochemi-
cal criteria (eg basal cytokeratins, actin, calponin,
caldesmon, S100 protein) [25–27].
As part of our investigation of genetic changes in pre-inva-
sive breast disease, we have shown that loss of heterozy-
gosity identified in invasive cancer is already present
independently in ‘normal’ luminal and myoepithelial cells
[28]. This suggests that there was a common precursor
cell that acquired the mutation prior to differentiation into
the two epithelial cell types. Some cells within the lobules
are difficult to categorise, morphologically and ultrastruc-
turally, into luminal or myoepithelial and it has been sug-
gested that these ‘intermediate’ or ‘indeterminate’ cells are
the precursors of the two epithelial cell types. It therefore
seems odd that tumours exhibiting myoepithelial differenti-
ation should be so rare in clinical practice; in contrast, for
example, to the salivary gland.
The morphology of myoepithelial carcinomas is different to
tumours derived from luminal cells. The myoepithelial carci-
nomas resemble sarcomas by having a predominantly
spindle cell growth pattern [20,23]. Although there are only
a few reports in the literature, approximately 50% of the
published cases followed an aggressive course [20]. We
carried out comparative genomic hybridisation analysis on
10 pure myoepithelial carcinomas [29] and compared the
data with that of ductal carcinomas–NOS. The most strik-
ing observation was the paucity of alterations in myoepithe-
lial carcinomas (mean, 2.1) compared with ‘ordinary’ breast
carcinomas with luminal differentiation (mean, 5.4 in
Grade I; mean, 11.7 in Grade III) [30–34]. The data are
especially surprising in view of the aggressive morphology
and behaviour of myoepithelial carcinomas. Seven out of
10 tumours were larger than 2cm in size and four out of
seven patients for whom follow-up information was avail-
able had died within 6 years of diagnosis. None of the alter-
ations identified in myoepithelial carcinomas were unique,
and they have been previously described in invasive breast
carcinomas with luminal phenotype [30–34]. Although
there was considerable overlap in the genetic profile of the
two distinct epithelial tumour types, some of the most
common alterations described in ductal carcinomas, such
as gains of 1q, 8q and 20q, and losses of 1p, 8p and 13q
[30–34], were not identified in myoepithelial carcinomas.
On the assumption that the two cell types are derived from
a common precursor cell [28], genetic alterations that
overlap between luminal and myoepithelial tumours must
have occurred within precursor cells prior to differentiation
into the two epithelial cell types. Those alterations, which
do not overlap, would have to occur subsequent to differ-







































investigate this fact, as ductal carcinoma and myoepithelial
carcinoma was present within the same tissue block. Loss
at 17p was seen in both tumour types. Only one other
alteration was seen in the myoepithelial tumour, while the
ductal carcinoma showed 13 other alterations. We would
therefore hypothesise that loss at 17p occurred within a
‘stem cell/precursor cell’, while alterations at other loci
occurred subsequent to differentiation into the two epithe-
lial cell types. We cannot formally exclude the possibility
that the myoepithelial cell with 17p loss was derived from
the luminal cell, as has been suggested recently [35].
However, unlike some other laboratories [36], we interpret
our own extensive studies of separated luminal and myoep-
ithelial cells in vitro as showing no evidence of any lability
or interchangeability between the two basic epithelial cell
types, either in bulk culture or as clones. We believe that
the enhanced proliferative potential of the cultured human
myoepithelial cell is the likely source of apparent hetero-
geneity in established cultures.
Since invasive ductal carcinomas exhibit a large number of
alterations, it has been difficult to differentiate between patho-
genic mutations and non-specific mutations due to genomic
instability. Myoepithelial cells, in contrast, appear resistant to
transformation, and myoepithelial carcinomas exhibit few
genetic alterations. Since the alterations identified in myoep-
ithelial carcinomas are also those seen in ductal carcinomas,
these alterations are likely to be pathogenetically significant in
breast carcinogenesis. The relatively few genetic alterations in
otherwise aggressive neoplasms lead us to propose that
myoepithelial tumours may be a better model than ductal car-
cinomas–NOS for the delineation of genes important in
breast tumorigenesis. These data also provide a tool with
which to investigate the significance of apparent myoepithelial
differentiation in morphologically ductal carcinoma–NOS. The
presence of specific genetic changes should discriminate
between entrapped non-malignant cells and true tumour cells
showing myoepithelial differentiation. Furthermore, the pat-
terns of such changes, if present, could throw light on the
clonal evolution within such cancers.
There is no doubt, even allowing for under-recognition of
the contribution of myoepithelial cells to breast cancer,
that the cells represent less than one-fifth of all cancers.
The possible reasons for the resistance to transformation
of this cell range from the simplistic to the untestable. As a
relatively mitotically quiescent cell [37], it may simply not
be as susceptible to tumorigenesis as the cycling luminal
cell. Alternatively, or in addition, it could possess a greater
DNA repair capacity, a hypothesis that is directly testable
using separated cells. Another possibility is that myoep-
ithelial cells express a greater range of tumour suppressor
functions that need to be inactivated before a malignant
phenotype is acquired. However, this seems unlikely in
light of the data from our laboratory [29] that myoepithelial
carcinomas, which are generally aggressive, show fewer
genetic alterations. The low proliferation index of the
myoepithelium in adult humans highlights another extraor-
dinary feature of its behaviour. Studies with separated
human cells have shown that, in vitro, myoepithelial cells
can re-enter the cell cycle very rapidly and proliferate very
fast [14]. As clones can be obtained from at least 50% of
such separated cells, this is clearly not a property of rare
stem cells, but extends to the majority of the functionally
differentiated cells. This potential proliferative capacity
emphasises the paradox of their failure to transform
because they are clearly not a permanently postmitotic
population. The presence of cycling cells of this pheno-
type in the pregnant human breast [38] further attests to
their innate proliferative potential. Their proliferation in vitro
has, in a practical context, caused much grief in studies of
unseparated breast epithelial cells, the culture of tumour
samples, many of which are still surrounded by myoepithe-
lial cells, and in the spontaneous or engineered establish-
ment of cell strains and lines. Some of the latter, which
purport to be the appropriate controls for breast malig-
nancy, express basal rather than luminal characteristics,
including basal cytokeratins and specialised junctional
proteins such as hemidesmosome components. It is fasci-
nating but appalling to observe such differences being
highlighted in complex transcriptional profiling experiments
[39] without the penny dropping! The advent of improved
methods of human cell immortalisation, combined with the
use of pre-separated characterised cells, does enable
more appropriate cell line models to be developed [40].
Matched pairs of luminal and myoepithelially derived lines
can also be developed for further investigation of normal
functional interactions. The reproducible development of
similar lines from malignant breast epithelial cells, be they
luminal or myoepithelial in phenotype, remains a major
challenge of breast tumour biology and pathology.
Conclusion
The myoepithelial cell is the Cinderella rather than the ugly
sister of mammary cell biology. Its role and potential have
been under-recognised. We believe that it will play an
increasingly important part in delineating and understand-
ing the events in breast physiology and pathology.
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